Isah J. Muhammad
Research Subjects
Isah J. Muhammad has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Abdullahi Yunusa Idris
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sceinces, Ahmadu Bello University, Zaria, Nigeria
1 shared publication - Ahmed Rufa'I1 shared publication
- Aliyu Muhammad Musa
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sceinces, Ahmadu Bello University, Zaria, Nigeria
1 shared publication - Asmau Nasiru Hamza
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Zaria 810107, Kaduna State, Nigeria
1 shared publication - Halimatu S. Hassan
Department of Pharmaceutical and Medicinal Chemistry, Ahmadu Bello University, Zaria 810211, Nigeria
1 shared publication - Mohammed Garba Magaji
Department of pharmacology and therapeutics, Ahmadu Bello University, Zaria
1 shared publication
Latest Publications
- Open Access
- 31 July 2026
- Published by Scifiniti Publishing in Molecular Modeling Connect
- Vol. 3 (1) , 1-10
Molecular Docking and ADME Profiling of N-(Substituted-1,3-benzothiazol-2-yl)benzamide Derivatives as Potential Anticonvulsant Agents
Amides represent a class of organic compounds with a variety of biological potential and anticonvulsant properties.This study aimed to evaluate the pharmacokinetic properties and molecular interactions of 15 N-(substituted-1,3-benzothiazol-2-yl)benzamide derivatives with two key epilepsy-related targets, γ-aminobutyric acid aminotransferase (GABA-AT) and activated open sodium ion channel proteins, in order to assess their potential anticonvulsant activity. Crystal structures of GABA-AT (PDB ID: 1OHW) and the sodium ion channel (PDB ID: 5HVX) were obtained from the RCSB Protein Data Bank. Molecular docking was performed using AutoDock Vina following protein preparation in Chimera v1.11.2. Post-docking analysis was conducted using Chimera and Discovery Studio Visualizer. ADME properties were also predicted. ADME analysis showed high gastrointestinal absorption for all compounds except compound 5. Docking results revealed that seven compounds (Cp1, Cp3, Cp7, Cp10, Cp12, Cp13, and Cp14) exhibited interaction profiles similar to vigabatrin, while three (Cp10, Cp13, and Cp14) aligned with lamotrigine. These compounds demonstrated favorable binding interactions with both targets. The docking analysis suggest that selected N-(substituted-1,3-benzothiazol-2-yl)benzamide derivatives, particularly Cp1, Cp3, Cp7, Cp10, Cp12, Cp13, and Cp14 were identified as the most promising lead candidates, with significant potential for anticonvulsant activity.
- 31 July 2026
- Published by Scifiniti Publishing in Molecular Modeling Connect
- Vol. 3 (1) , 1-10
Open AccessMolecular Docking and ADME Profiling of N-(Substituted-1,3-benzothiazol-2-yl)benzamide Derivatives as Potential Anticonvulsant Agents
Amides represent a class of organic compounds with a variety of biological potential and anticonvulsant properties.This study aimed to evaluate the pharmacokinetic properties and molecular interactions of 15 N-(substituted-1,3-benzothiazol-2-yl)benzamide derivatives with two key epilepsy-related targets, γ-aminobutyric acid aminotransferase (GABA-AT) and activated open sodium ion channel proteins, in order to assess their potential anticonvulsant activity. Crystal structures of GABA-AT (PDB ID: 1OHW) and the sodium ion channel (PDB ID: 5HVX) were obtained from the RCSB Protein Data Bank. Molecular docking was performed using AutoDock Vina following protein preparation in Chimera v1.11.2. Post-docking analysis was conducted using Chimera and Discovery Studio Visualizer. ADME properties were also predicted. ADME analysis showed high gastrointestinal absorption for all compounds except compound 5. Docking results revealed that seven compounds (Cp1, Cp3, Cp7, Cp10, Cp12, Cp13, and Cp14) exhibited interaction profiles similar to vigabatrin, while three (Cp10, Cp13, and Cp14) aligned with lamotrigine. These compounds demonstrated favorable binding interactions with both targets. The docking analysis suggest that selected N-(substituted-1,3-benzothiazol-2-yl)benzamide derivatives, particularly Cp1, Cp3, Cp7, Cp10, Cp12, Cp13, and Cp14 were identified as the most promising lead candidates, with significant potential for anticonvulsant activity.